Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Byrd

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Gastroenterology|September 14, 2004
A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancerRobert S Bresalier, James C Byrd, David Tessler, et al.
Cancer Research|December 3, 2005
Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genesNachman Mazurek, Yun Jie Sun, Janet E Price, et al.
Breast Cancer Research : BCR|October 1, 2016
Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cellsMatthias Ilmer, Nachman Mazurek, Michael Z Gilcrease, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Gastroenterology|September 14, 2004
A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancerRobert S Bresalier, James C Byrd, David Tessler, et al.
Cancer Research|December 3, 2005
Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genesNachman Mazurek, Yun Jie Sun, Janet E Price, et al.
Breast Cancer Research : BCR|October 1, 2016
Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cellsMatthias Ilmer, Nachman Mazurek, Michael Z Gilcrease, et al.
Pageof 3